Respiratory Virus Season in 2026: What to Know About COVID-19, Flu, RSV, and Staying Protected

Practical takeaway: COVID-19, influenza (flu), and respiratory syncytial virus (RSV) continue to circulate across the United States in seasonal waves. Most infections are mild, but older adults, infants, pregnant people, and those with chronic conditions remain at higher risk for severe illness. Staying up to date on vaccines, testing early if symptoms develop, and seeking treatment promptly if you’re high risk can reduce complications.

Respiratory virus season is no longer limited to a single winter spike. Since the COVID-19 pandemic, patterns have shifted. According to the Centers for Disease Control and Prevention (CDC), the U.S. now sees overlapping waves of COVID-19, flu, and RSV throughout fall and winter, with occasional off-season increases.

Which viruses are circulating now?

National surveillance from the CDC shows continued circulation of:

Influenza (flu) – A seasonal virus that can cause fever, cough, body aches, and fatigue.
COVID-19 – Now considered an endemic respiratory virus with periodic surges.
RSV – A common virus that can be serious for infants and older adults.

Other viruses, such as rhinoviruses (common cold viruses) and seasonal coronaviruses, are also circulating but typically cause milder illness.

The CDC’s respiratory virus updates emphasize that while overall hospitalization rates fluctuate, severe outcomes remain concentrated in adults 65 and older, infants, and people with underlying conditions like heart disease, lung disease, diabetes, obesity, or weakened immune systems.

Symptoms: They Overlap More Than You Think

COVID-19, flu, and RSV share many symptoms, including:

Fever or chills
Cough
Sore throat
Runny or stuffy nose
Fatigue
Muscle aches
Headache

RSV in infants may present differently, including poor feeding, irritability, wheezing, or pauses in breathing. In older adults, symptoms may be less obvious but can still progress to pneumonia.

Because symptoms overlap, testing can help clarify which virus is responsible—especially for people at higher risk who may qualify for antiviral treatment.

Vaccines: What’s Recommended in 2026?

Public health guidance from the CDC and FDA continues to recommend:

Annual influenza vaccination for everyone 6 months and older.
Updated COVID-19 vaccination for eligible age groups to reduce severe disease and hospitalization.
RSV vaccination for adults 60 and older (after discussion with a clinician) and for pregnant people during recommended gestational windows to protect newborns.
Monoclonal antibody protection for certain infants during RSV season, per pediatric guidance.

Vaccines are designed primarily to reduce severe illness, hospitalization, and death. They do not completely prevent infection, but evidence reviewed by CDC advisory committees shows they significantly lower the risk of complications.

Insurance plans, including Medicare and most private coverage under the Affordable Care Act, generally cover recommended vaccines without cost-sharing when given by in-network providers.

Treatment: Early Action Matters

If you are at higher risk for severe illness, early treatment can make a difference.

Influenza: Antiviral medications such as oseltamivir are most effective when started within 48 hours of symptom onset.
COVID-19: Oral antiviral medications such as nirmatrelvir-ritonavir (Paxlovid) are authorized by the FDA for eligible high-risk patients and work best when started early.
RSV: Treatment is mainly supportive (fluids, oxygen if needed), though preventive strategies are available for certain groups.

Not everyone needs antivirals, but older adults and those with chronic conditions should contact a clinician promptly if symptoms develop.

Who Is at Higher Risk?

According to CDC data, groups at higher risk for severe respiratory illness include:

Adults 65 and older
Infants, especially under 6 months
Pregnant people
People with heart, lung, kidney, or metabolic disease
People with weakened immune systems
Residents of long-term care facilities

For these groups, even a “mild” respiratory infection can escalate quickly.

Prevention Beyond Vaccines

Layered prevention remains important, especially during surges:

Stay home when sick.
Wash hands regularly with soap and water.
Improve indoor ventilation when possible.
Consider high-quality masks in crowded indoor settings during peak transmission.
Cover coughs and sneezes.

These measures are particularly important around medically vulnerable individuals.

Oral Health and Respiratory Illness

Good oral hygiene does not prevent respiratory viruses, but maintaining oral health supports overall immune function and reduces the bacterial burden in the mouth. For older adults and those in long-term care settings, poor oral hygiene has been associated with increased risk of bacterial pneumonia, according to research indexed in PubMed and supported by the National Institutes of Health. While viruses cause flu and COVID-19, secondary bacterial infections can complicate recovery.

When to Seek Urgent Care

Seek immediate medical care if you or a loved one develops:

Trouble breathing
Chest pain or pressure
New confusion
Severe dehydration
Bluish lips or face
Symptoms that worsen after initial improvement

Parents of infants should seek care for difficulty breathing, poor feeding, or unusual lethargy.

What This Means for Readers

Respiratory viruses remain a regular part of life in the United States. The key shifts in recent years are better surveillance, updated vaccines, and clearer guidance on early treatment. Most healthy people recover without complications. But for vulnerable groups, prevention and prompt action still matter.

If you haven’t reviewed your vaccination status this season, now is a reasonable time to do so. If symptoms develop and you’re in a higher-risk category, testing and early treatment can reduce the chance of severe outcomes.

Staying informed through reliable public health sources helps families, schools, and workplaces make balanced decisions without panic.

Sources

Centers for Disease Control and Prevention (CDC) – Respiratory Virus Guidance and Surveillance Updates
U.S. Food and Drug Administration (FDA) – Antiviral Authorizations and Safety Information
National Institutes of Health (NIH) – Research on Respiratory Infections and Secondary Complications

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.